Precision Biosciences Inc. has received pre-IND regulatory feedback from the FDA and ex-U.S. agencies providing alignment and clarity on Precision's final IND/CTA-enabling preclinical plans and clinical strategy for PBGENE-HBV.

Vantai Inc. and Bristol Myers Squibb Co. have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest.

The gastrin-releasing peptide receptor (GRPR) is overexpressed in several types of tumors and is considered a target for theranostic strategies.

Investigators from the Chinese Academy of Medical Sciences & Peking Union Medical College presented data from a study that investigated the regulatory mechanisms of intestinal epithelial cell (IEC) death and intestinal inflammation.

Genome sequencing has identified several single-nucleotide polymorphisms (SNPs) tied to osteoporosis, but most of them are located in noncoding regions. Investigators identified a SNP which impacted the YY2-PAPSS2 axis and risk of osteoporosis; the PAPSS2 gene encodes bifunctional 3’-phosphoadenosine 5’-phosphosulfate synthase 2.

Researchers from the Yale University School of Medicine have developed a novel murine model of Gaucher disease type I with the aim to investigate the impact of GBA1 deficiency on hematopoiesis and the immune system, in order to elucidate potential therapeutic targets.